MyoScreen™ Discovery Platform

CYTOO provides unprecedented research capabilities that address the specific challenges our clients encounter over the entire drug development process.

This is made possible by our unique expertise in micropatterning technology and extensive experience in creating in vitro models of human muscle pathologies as well as advanced analytical methods.

The MyoScreen technology

CYTOO’s MyoScreen technology is designed to facilitate advanced muscle cell research. By leveraging advanced micropatterning techniques, MyoScreen creates highly controlled and standardized environments for the culture and differentiation of myoblasts. This approach ensures uniformity and reproducibility, providing it ideal for high-throughput and high-content analysis, drug discovery, and in-depth biological studies. With MyoScreen, we can achieve remarkable precision and physiological relevance, paving the way for new insights into muscle biology and disease mechanisms, and supporting your drug discovery efforts.

Three main competitive advantages

Physiological relevance (patients cells, superior maturation)

Standardization (reduced variability, statistical power)

Automation ready (high-throughput, quantitative analysis)

From Patient to Plate:
The Power of Human Primary Cells

The predictive power of Myoscreen discovery platform lies in its use of cells derived directly from healthy or diseased patients.

We have the capacity to model different types of pathologies affecting the muscle. For genetically driven diseases, we can work with patient-derived myoblasts. We already possess an extensive patient cell bank and have established collaborations with biobanks to meet our partners’ needs. Culture conditions can also be tailored to mimic pathological environments.

DMD

DM1

SMA

DM2

FSHD

Pompe disease

Muscle wasting

Cardiometabolic diseases

Setting Higher Expectations for Reproducibility
and Standardization

MyoScreen’s micropatterning technology ensures a high level of standardization in muscle cell research. By creating uniform and controlled environments, MyoScreen minimizes variability and enhances the consistency of experimental outcomes.

This standardization is crucial for generating reliable and reproducible data, making MyoScreen an invaluable tool for scientific and pharmaceutical applications.

Conventional

In conventional cell culture methods, myotubes often exhibit significant heterogeneity in terms of size and shape, resulting in a complex network that is poorly compatible with High Content Analysis approaches. This variability can lead to inconsistent experimental results and complicate data interpretation.

CYTOO

In contrast, MyoScreen technology produces aligned and linear myotubes, ensuring standardization and uniformity. These standardized myotubes can be easily quantified using High Content Analysis, facilitating more accurate and reproducible research outcomes.

Improved Myotube Maturation

MyoScreen enables the formation of myotubes with a high level of maturation. Through its micropatterning technology, MyoScreen provides a controlled environment that promotes efficient myoblast fusion and differentiation.

This results in myotubes that are highly mature, uniform, and physiologically relevant, making them ideal for accurate and reliable research in muscle biology and drug discovery.

The optimized microenvironment provided by MyoScreen promotes more efficient myoblast fusion and differentiation, and favors myotubes maturation, resulting in more physiologically relevant and functional muscle fibers.

Quantitative Analysis for Complex Cellular Readouts

Our platform combines advanced image analysis with tailored data exploration to extract meaningful, decision-supporting readouts from high-content assays. We quantify subtle phenotypes, spatial distributions, and texture-based features across thousands of cells, helping partners capture the complexity of cellular responses.

In addition to primary metrics, we apply custom analysis workflows to compare conditions, highlight compound-specific effects, and identify biologically relevant trends, adapted to both exploratory and confirmatory goals. Where relevant, we implement machine learning models to support classification tasks or uncover hidden structures in the data and images to build phenotypic models of the cells.

This layered approach reveals insights often missed by classical cellular image analysis, increasing experimental value and enabling more confident decisions across a programme.

Do you want to know more about our services?

Our publications

MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1

MyoScreen, a High-Throughput Phenotypic Screening Platform Enabling Muscle Drug Discovery

MyoScreen : a high-content-based doiscovery platform to model and screen key metabolic processes in human skeletal muscle

AI-powered cell profiling enables the quantitative and functional evaluation of therapies targeting muscle disorders in patient-derived myotubes

MyoScreen, a drug discovery platform for disease modeling and screening of compounds restoring muscle health

Screenable MyoScreen pompe early-onset and late-onset skeletal muscle for drug discovery

Development and validation of a high throughput screening platform to enable target identification in skeletal muscle cells from Duchenne Muscular Dystrophy (DMD) patients